Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

Keyphrases

• Percutaneous Coronary Intervention 100%
• Glycoprotein IIb/IIIa Inhibitors 100%
• Cangrelor 100%
• Clopidogrel 36%
• Confidence Interval 36%
• Odds Ratio 36%
• PinT 18%
• Myocardial Infarction 9%
• Ischemia 9%
• All-cause Mortality 9%
• Safety Endpoints 9%
• Efficacy Endpoint 9%
• Revascularization 9%
• Platelet Inhibition 9%
• Optimal Management 9%
• Baseline Characteristics 9%
• Composite Endpoint 9%
• Ischemic Complication 9%
• Eptifibatide 9%
• Well-balancing 9%
• Bleeding Risk 9%
• Bleeding Rate 9%
• Primary Safety 9%
• Stent Thrombosis 9%
• GUSTO 9%
• Life-threatening Bleeding 9%
• P2Y12 Antagonists 9%
• Site Investigators 9%
• Patient-level Analysis 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Fibrinogen Receptor 100%
• Cangrelor 100%
• Clopidogrel 36%
• Bleeding 18%
• Heart Infarction 9%
• All Cause Mortality 9%
• Ischemia 9%
• Stent Thrombosis 9%
• Eptifibatide 9%